Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery

Phase 4 Completed 84 enrolled University of Colorado, Denver

RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to compare two medications that reverse muscle paralysis at the end of kidney transplant surgery with the goal of reducing residual muscle weakness and insufficient respiratory function after surgery.

Timeline

Start: 2021-02-02
Primary completion: 2023-09-30
Completion: 2023-10-30

Publications

Stewart E, Kaizer A, Fioravanti J, Russell N, Hendrickse A, Adams M, Pshak T, Fernandez-Bustamante A. Postoperative residual neuromuscular blockade and hypoventilation after rocuronium and sugammadex or neostigmine for kidney transplantation: A randomized clinical trial. J Clin Anesth. 2026 Apr;111:112174. doi: 10.1016/j.jclinane.2026.112174. Epub 2026 Mar 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Neostigmine	Other / unclassified	0.03 mg/kg	Intravenous
Comparator	Neostigmine	Other / unclassified	0.07 mg/kg	Intravenous
Subject	Sugammadex	Other / unclassified	2 mg/kg	Intravenous
Subject	Sugammadex	Other / unclassified	4 mg/kg	Intravenous

Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery

Summary

Timeline

Publications

Drugs

Indications